Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Scholar Rock Holding Corporation SRRK NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$55.67
+12.4%

Scholar Rock Holding Corporation (SRRK) is a Biotechnology company in the Healthcare sector, currently trading at $49.53. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is SRRK = $56 (+12.4% upside).

Valuation: SRRK trades at a trailing Price-to-Earnings (P/E) of -15 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.61.

Net income is $378M (loss), growing at -42.6%/yr. Net profit margin is 0% (thin). Gross margin is 70.2% (+0 pp trend).

Balance sheet: total debt is $109M against $245M equity (Debt-to-Equity (D/E) ratio 0.44, conservative). Current ratio is 6.95 (strong liquidity). Debt-to-assets is 26.9%. Total assets: $404M.

Analyst outlook: 12 / 12 analysts rate SRRK as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 65/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 58/100 (Partial), Future 88/100 (Pass), Income ?/100 (Fail).

$55.67
▲ 12.4% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Scholar Rock Holding Corporation, the average price target is $55.67, with a high forecast of $60.00, and a low forecast of $50.00.
Highest Price Target
$60.00
Average Price Target
$55.67
Lowest Price Target
$50.00

SRRK SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 65/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 88/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SRRK

✓
VALUE Pass
65/100
SRRK trades at a trailing Price-to-Earnings (P/E) of -15 (S&P 500 average ~25). Forward PEG 0.61 — Peter Lynch undervalued (≤1.0). Trailing PEG 6.89. Analyst consensus target is $56, implying +13.1% from the current price $50. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
SRRK: -100%/yr revenue is, -42.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet SRRK: Debt-to-Equity (D/E) ratio 0.44 (conservative), Current ratio is 6.95 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
SRRK: Gross margin is 70.2% (+0 pp trend), $6B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
88/100
Analyst outlook: 12 / 12 analysts rate SRRK as buy (100%). Analyst consensus target is $56 (+13.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range22.71-50.5
Volume1.42M
Avg Volume (30D)1.35M
Market Cap$5.69B
Beta (1Y)0.69
Share Statistics
EPS (TTM)-3.29
Shares Outstanding$114.7M
IPO Date2018-05-25
Employees128
CEODavid L. Hallal
Financial Highlights & Ratios
Gross Profit$-1.66M
EBITDA$-369.39M
Net Income$-377.94M
Operating Income$-384.65M
Total Cash$367.56M
Total Debt$108.92M
Net Debt$-214.61M
Total Assets$404.27M
Price / Earnings (P/E)-15.1
Analyst Forecast
1Y Price Target$56.50
Target High$60.00
Target Low$50.00
Upside+14.1%
Rating ConsensusBuy
Analysts Covering12
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS80706P1030

Price Chart

Track all markets on TradingView
SRRK
Scholar Rock Holding Corporation ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
22.71 52WK RANGE 50.50

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 IDYA
IDYA
IDEAYA Biosciences, Inc.
$32.35
-1.43%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message